Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. [electronic resource]
Producer: 20070801Description: 299-303 p. digitalISSN:- 1472-4472
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Denosumab
- Humans
- Injections, Subcutaneous
- Osteoporosis -- drug therapy
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B -- immunology
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.